The deregulated kinase activity of p210-BCR/ABL oncoproteins, hallmark of chronic myelogenous leukaemia (CML), induces and sustains the leukaemic phenotype, and contributes to disease progression. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.